✦ LIBER ✦

Late effect of Atomic bomb radiation on myeloid disorders: leukemia and myelodysplastic syndromes

✍ Scribed by Hideki Tsushima; Masako Iwanaga; Yasushi Miyazaki

Book ID: 113099238
Publisher: Carden Jennings Publishing
Year: 2012
Tongue: English
Weight: 378 KB
Volume: 95
Category: Article
ISSN: 0925-5710
DOI: 10.1007/s12185-012-1002-4

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Loss of heterozygosity identifies geneti

Loss of heterozygosity identifies genetic changes in chronic myeloid disorders, including myeloproliferative disorders, myelodysplastic syndromes and chronic myelomonocytic leukemia

✍ O'Malley, Dennis P; Orazi, Attilio; Dunphy, Cherie H; Coleman, Benjamin R; Marks 📂 Article 📅 2007 🏛 Nature Publishing Group 🌐 English ⚖ 96 KB

P-109 Impact of radiation exposure on th

P-109 Impact of radiation exposure on the prognosis of myelodysplastic syndromes in Nagasaki atomic bomb survivors: A preliminary analysis

✍ Matsuo, M.; Iwanaga, M.; Hata, T.; Tsushima, H.; Ando, K.; Kondo, H.; Soda, M.; 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 68 KB

Proposals for standardized protocols for

Proposals for standardized protocols for cytogenetic analyses of acute leukemias, chronic lymphocytic leukemia, chronic myeloid leukemia, chronic myeloproliferative disorders, and myelodysplastic syndromes

✍ Claudia Haferlach; Harald Rieder; Debra M. Lillington; Nicole Dastugue; Anne Hag 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 140 KB

## Abstract The impact of cytogenetic characterization based on chromosome banding analyses and fluorescence in situ hybridization on clinical decision making has increased dramatically during recent years. Therefore, laboratory techniques have to be optimized to provide reliable results for optima

Risk of myelodysplastic syndrome and acu

Risk of myelodysplastic syndrome and acute myeloid leukemia post radiation treatment for breast cancer: a population-based study

✍ Henry Kaplan, Judith Malmgren, Anneclaire J. De Roos 📂 Article 📅 2012 🏛 Springer US 🌐 English ⚖ 163 KB

Effectiveness and safety of different az

Effectiveness and safety of different azacitidine dosage regimens in patients with myelodysplastic syndromes or acute myeloid leukemia

✍ García-Delgado, Regina; de Miguel, Dunia; Bailén, Alicia; González, José Ramón; 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 611 KB

Results of imatinib mesylate therapy in

Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders

✍ Jorge Cortes; Francis Giles; Susan O'Brien; Deborah Thomas; Maher Albitar; Mary 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 92 KB 👁 2 views

## Abstract ## BACKGROUND Imatinib mesylate is a selective tyrosine kinase inhibitor of c‐abl, bcr/abl, c‐kit, and platelet‐derived growth factor‐receptor (PDGF‐R). c‐kit is expressed in most patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) and PDGF has been implicated